Published in Kidney Int on January 01, 2003
Safety of intravenous iron formulations: facts and folklore. Blood Transfus (2014) 1.25
Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter (2011) 1.02
Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol (2007) 0.93
Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. NDT Plus (2010) 0.93
Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res (2008) 0.87
Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clin J Am Soc Nephrol (2010) 0.86
Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clin Drug Investig (2016) 0.84
Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol (2006) 0.81
Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer. Nephrol Dial Transplant (2008) 0.75
Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study. PLoS One (2017) 0.75
Effects of early parenteral iron combined erythropoietin in preterm infants: A randomized controlled trial. Medicine (Baltimore) (2017) 0.75
[Indications and practical management of parenteral iron therapy]. Wien Klin Wochenschr (2003) 0.75
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care (2007) 29.89
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med (2000) 8.32
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol (2006) 6.64
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med (2002) 5.72
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis (2008) 3.87
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med (2013) 3.15
Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am Soc Nephrol (2002) 3.04
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol (2004) 3.02
Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med (2006) 3.00
Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med (2008) 2.99
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension (2008) 2.99
Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med (2003) 2.94
Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis (2008) 2.74
Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2010) 2.68
Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.61
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc (2010) 2.55
A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol (2009) 2.53
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis (2011) 2.49
Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol (2005) 2.49
Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol (2008) 2.43
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol (2006) 2.41
Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol (2006) 2.32
Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis (2009) 2.25
Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int (2005) 2.19
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (2009) 2.17
Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens (2013) 2.11
Survival advantage of black patients with kidney disease after acute myocardial infarction. Clin J Am Soc Nephrol (2006) 2.08
Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study. Catheter Cardiovasc Interv (2002) 2.07
Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med (2011) 2.06
Novel clinical trial designs for the development of new antiretroviral agents. AIDS (2012) 2.01
Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. Hypertension (2003) 1.99
Acute kidney injury and mortality in hospitalized patients. Am J Nephrol (2012) 1.99
Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol (2013) 1.97
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis (2006) 1.97
Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol (2011) 1.96
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol (2007) 1.92
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol (2012) 1.90
Associations of pretransplant weight and muscle mass with mortality in renal transplant recipients. Clin J Am Soc Nephrol (2011) 1.90
Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes. Hum Mol Genet (2010) 1.89
Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight. Hypertension (2009) 1.87
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med (2006) 1.87
Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res (2010) 1.79
Cardiovascular risk factors in CKD associate with both ESRD and mortality. J Am Soc Nephrol (2013) 1.78
Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis (2003) 1.77
Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol (2007) 1.76
Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. Clin J Am Soc Nephrol (2012) 1.75
Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.75
Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis (2011) 1.74
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion (2008) 1.73
Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol (2012) 1.69
Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int (2012) 1.67
ACE and ACE2 activity in diabetic mice. Diabetes (2006) 1.66
Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis (2006) 1.66
Association between urinary albumin excretion and coronary heart disease in black vs white adults. JAMA (2013) 1.65
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int (2011) 1.64
Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. Clin J Am Soc Nephrol (2013) 1.63
A longitudinal study of kidney structure and function in adults. Nephrol Dial Transplant (2009) 1.63
Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol (2011) 1.62
Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injury. Nephrol Dial Transplant (2013) 1.61
Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol (2007) 1.61
Hyponatremia in community-acquired pneumonia. Am J Nephrol (2007) 1.59
Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.54
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int (2003) 1.53
Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int (2013) 1.52
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (2009) 1.52
Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol (2010) 1.52
Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol (2010) 1.51
Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron (2014) 1.50
Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.50
Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol (2011) 1.50
Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg (2008) 1.50
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.49
Association of family history of ESRD, prevalent albuminuria, and reduced GFR with incident ESRD. Am J Kidney Dis (2011) 1.48
Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC). J Biol Chem (2002) 1.48
Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension (2004) 1.48
Association of pretransplant serum phosphorus with posttransplant outcomes. Clin J Am Soc Nephrol (2011) 1.48
Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation. Am J Nephrol (2011) 1.47
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant (2008) 1.46
Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. Nephrol Dial Transplant (2011) 1.46
Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol (2004) 1.46
Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther (2013) 1.43
Albuminuria and racial disparities in the risk for ESRD. J Am Soc Nephrol (2011) 1.42
Improving outcomes from acute kidney injury. J Am Soc Nephrol (2007) 1.42
A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int (2003) 1.40
Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol (2007) 1.40
Trended cosinor change model for analyzing hemodynamic rhythm patterns in hemodialysis patients. Hypertension (2007) 1.39